Upstream Bio said with its Q2 2026 results that it plans to start Phase 3 trials of verekitug in severe asthma and CRSwNP in Q1 2027. The company is also advanc

BWB News TV • 2026-08-11 11:12 UTC • By Billy Odell Tucker-Robinson

Upstream Bio said with its Q2 2026 results that it plans to start Phase 3 trials of verekitug in severe asthma and CRSwNP in Q1 2027. The company is also advancing the candidate in COPD, extending its respiratory pipeline focus.

Share this article

𝕏 X / Twitter Facebook LinkedIn WhatsApp

📚 More from Billy’s World

📰 Banking With Billy News All breaking financial news & market analysis 📚 Banking With Billy Books Deep-dive books on every financial story 💬 Join the Community discord.gg/VHxwmR5j4Y 🎥 Banking With Billy on YouTube Live streams & market commentary

Banking With Billy News Network — bankingwithbilly.com
Discord: discord.gg/VHxwmR5j4Y • YouTube: @BankingWithBilly